Comparing Rosiglitazone and Standard Diabetes Treatments
Author Information
Author(s): Home P D, Jones N P, Pocock S J, Beck-Nielsen H, Gomis R, Hanefeld M, Komajda M, Curtis P
Primary Institution: Newcastle Diabetes Centre and Newcastle University UK
Hypothesis
To compare glucose control over 18 months between rosiglitazone oral combination therapy and combination metformin and sulphonylurea in people with Type 2 diabetes.
Conclusion
Rosiglitazone in combination with metformin or sulphonylurea is as effective as the standard combination of metformin + sulphonylurea in lowering HbA1c over 18 months, but is associated with greater weight gain.
Supporting Evidence
- At 18 months, HbA1c reduction was similar with rosiglitazone and sulphonylurea.
- Body weight was significantly increased with rosiglitazone compared to sulphonylurea and metformin.
- Increased insulin sensitivity was greater with rosiglitazone than with metformin or sulphonylurea.
Takeaway
This study looked at how well a diabetes medication called rosiglitazone works compared to two other common diabetes medicines. It found that rosiglitazone works just as well but can make people gain weight.
Methodology
A multicentre, parallel-group study comparing glucose control in participants with Type 2 diabetes on different medication regimens over 18 months.
Potential Biases
The open-label design may introduce bias in treatment adherence and reporting.
Limitations
The study was open-label and excluded clinically significant data, including adverse events.
Participant Demographics
Participants were aged 40–75 years, with a BMI > 25.0 kg/m2 and HbA1c > 7.0–9.0%.
Statistical Information
P-Value
0.003
Confidence Interval
95% CI −0.09, 0.23%
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website